HUTCHMED's Sovleplenib Meets Primary Endpoint in Phase III Trial for Warm Autoimmune Hemolytic Anemia
Key Insights
HUTCHMED's Phase III ESLIM-02 trial of sovleplenib successfully met its primary endpoint of durable hemoglobin response rate in adult patients with warm antibody autoimmune hemolytic anemia (search) in China.
The novel spleen tyrosine kinase (search) inhibitor demonstrated rapid and durable responses in wAIHA, the most common form of autoimmune hemolytic anemia (search) accounting for 75-80% of adult cases.
HUTCHMED plans to submit a New Drug Application to China's NMPA in the first half of 2026, marking a potential breakthrough for patients with limited treatment options.
HUTCHMED (China) Limited announced that the Phase III registration portion of the ESLIM-02 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (search) (Syk (search)) inhibitor, in adult patients with warm antibody autoimmune hemolytic anemia (search) (wAIHA) in China has successfully met its primary endpoint. The study demonstrated a durable hemoglobin response rate between weeks 5 and 24 of treatment, marking a significant milestone in the development of sovleplenib for this rare autoimmune blood disorder.
Disease Background and Unmet Need
Autoimmune hemolytic anemia (search) is an autoimmune disorder characterized by the destruction of red blood cells due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8-11%. wAIHA is the most common form of AIHA, accounting for about 75-80% of all adult AIHA cases.
Professor Fengkui Zhang of the Chinese Academy of Medical Sciences Blood Diseases Hospital (search), and one of the leading principal investigators of the ESLIM-02 study, explained the clinical significance: "Warm antibody autoimmune hemolytic anemia (search) is a highly heterogeneous and often chronically relapsing disease. Patients often experience symptoms like fatigue significantly impacting patients' quality of life. In severe cases, the disease can become life-threatening if not managed effectively."
Trial Design and Results
ESLIM-02 is a randomized, double blind, placebo-controlled China Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment. Results from the Phase II part of the study published in The Lancet Haematology in January 2025 demonstrated encouraging hemoglobin benefit compared with placebo, with overall response rate of 43.8% vs 0% in the first 8 weeks, and overall response rate of 66.7% during the 24 weeks of sovleplenib treatment (including patients that crossed over from placebo) with a favorable safety profile.
Professor Zhang noted the clinical impact: "The positive topline results from ESLIM-02 highlight sovleplenib's potential to deliver rapid and durable hemoglobin responses in wAIHA patients who have limited options after failing standard therapies. This could represent a meaningful advancement for managing this challenging condition."
Mechanism of Action
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase (search), also known as Syk (search). Syk is a major component in B-cell receptor (search) and Fc receptor (search) signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (FcγR) bearing macrophages is thought to be the pathogenic mechanism in wAIHA. Activated Syk (search) mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs. In addition, activation of Syk through the B-cell receptor (search) mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells. Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production.
Regulatory Timeline and Broader Development
HUTCHMED plans to submit the New Drug Application for sovleplenib for wAIHA to the China National Medical Products Administration (search) (NMPA) in the first half of 2026. Full results of the ESLIM-02 study will be submitted for presentation at an upcoming scientific conference.
In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (search) (ITP). Positive results from ESLIM-01, a Phase III trial in China of sovleplenib in patients with primary ITP, have been published in The Lancet Haematology. An NDA resubmission for sovleplenib for second-line ITP is planned in the first half of 2026.
HUTCHMED currently retains all rights to sovleplenib worldwide. Professor Bin Han of Peking Union Medical College Hospital and Professor Lianshan Zhang of The Second Hospital of Lanzhou University (search) were also co-leading Principal Investigators of the study.